Drugs for MRSA skin and soft-tissue infections

Medical Letter on Drugs and Therapeutics

Volumn 56, Issue 1442, 2014, Pages 39-40

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE FOSAMIL; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; DOXYCYCLINE; LINEZOLID; MINOCYCLINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEDIZOLID; TELAVANCIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ABSCESS; ANTIBIOTIC RESISTANCE; CELLULITIS; DEATH; FURUNCULOSIS; HUMAN; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NECROTIZING FASCIITIS; PNEUMONIA; RISK; SEPSIS; SKIN INCISION; SKIN INFECTION; SOFT TISSUE INFECTION; SURGICAL DRAINAGE;

ANTI-BACTERIAL AGENTS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS;

EID: 84900331309     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (8)

1. DA Talan et al. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. Clin Infect Dis 2011; 53:144.
2. R Dantes et al. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med 2013; 173:1970.
3. Drugs for bacterial infections. Med Lett Drugs Ther 2013; 11:65.
4. F Rossi et al. Transferable vancomycin resistance in a communityassociated MRSA lineage. N Engl J Med 2014; 370:1524.
5. Ceftaroline fosamil (Tefl aro) - a new IV cephalosporin. Med Lett Drugs Ther 2011; 53:5.
6. FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new boxed warning. Available at www.fda.gov/drugs/drugsafety/ucm369580.htm. Accessed May 5, 2014.
7. AJ Singer and DA Talan. Management of skin abscesses in the era of methicillin-resistant Staphylococcus aureus. N Engl J Med 2014; 370:1039.
8. C Liu et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52:285.